

WEB TABLES

Table A Randomised controlled trials of statins and disease events: individual trial data

Trial (acronym <sup>¶</sup> )	Cholesterol lowering drug	No of participants		Mean LDL cholesterol reduction (mmol/l)	Ischaemic heart disease events by time period								Strokes				Adverse effects of statins						
					≤ 1 year		1.1-2 years		2.1 - 5 years		> 5 years		all		fatal		Elevated ALT <sup>±</sup>		Elevated CPK <sup>§</sup>		Diagnosis of rhabdomyolysis		
		tr	plac		tr	plac	tr	plac	tr	plac	tr	plac	tr	plac	tr	plac	tr	plac	tr	plac	tr	plac	
<b>Without known vascular disease on entry</b>																							
ASCOT-LLA <sup>w165</sup>	atorvastatin	5168	5137	1.2	14	13		13	15	28	53	-	-	89	121	-	-	-	-	-	1	0	
AFCAPS/TexCAPS <sup>w166,w167</sup>	lovastatin	3304	3301	1.0	12	17*		14	19	27	49	4	10	-	-	-	-	18	11	21	21	1	2
EXCEL <sup>w40</sup> †	lovastatin	6582	1663	1.4	62	20		-	-	-	-	-	-	11	1	10	1	45	2	17	7	0	0
PROSPER <sup>w168</sup> †	pravastatin	2819	2913	1.1	86	101		91	111	115	144	-	-	135	131**	22	14	1	1	0	0	0	0
WOSCOPS <sup>w169</sup>	pravastatin	3302	3293	1.0	40	55		32	50	95	135	7	8	46	51	6	4	16	12	3	1	0	0
KAPS <sup>w170,w171</sup> †	pravastatin	224	223	1.6	3	2		2	4	0	2	-	-	2	4	0	1	4	3	-	-	-	-
<b>With known vascular disease on entry</b>																							
MIRACL <sup>w110,w172</sup>	atorvastatin	1538	1548	1.6	155	169		-	-	-	-	-	-	12	24	3	2	38	9	-	-	0	0
GREACE <sup>w173</sup>	atorvastatin	800	800	1.8	9	25		10	24	19	38	-	-	9	17	0	0	7	3	-	-	0	0
LIPS <sup>w174</sup>	fluvastatin	844	833	1.0	23	26		6	11	13	23	-	-	-	-	2	1	10	3	0	3	0	0
FLARE <sup>w175</sup>	fluvastatin	409	425	1.4	6	17		-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-
LCAS <sup>w176,w177</sup>	fluvastatin	157	164	0.6			7 6 ‡	-	-	-	-	-	-	0	0	0	0	2	0	1	2	-	-
Riegger et al <sup>w178</sup>	fluvastatin	187	178	1.0	2	5		-	-	-	-	-	-	0	0	0	0	0	0	0	1	-	-
Post CABG <sup>w179</sup>	lovastatin	676	675	1.1	10	8*		12	7	13	25	-	-	17	16	4	4	-	-	-	-	0	0
ACAPS <sup>w39</sup>	lovastatin	460	459	0.9	2	2		2	4	1	3	-	-	0	5	0	2	6	6	-	-	0	0
CCAT <sup>w180</sup>	lovastatin	165	166	1.2			7 7 ‡	-	-	-	-	-	-	2	0	0	0	-	-	-	-	-	-
Sahni et al <sup>w181</sup>	lovastatin	79	78	0.7	3	4		-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-
LRT <sup>w182</sup>	lovastatin	203	201	1.2	5	1		-	-	-	-	-	-	0	1	0	0	3	1	3	0	-	-
LIPID <sup>w183,w185</sup>	pravastatin	4512	4502	1.0	113	144		96	115	256	325	92	131	169	204	22	27	112	119	6	1	0	0
CARE <sup>w185,w187</sup>	pravastatin	2081	2078	1.0	59	59*		42	42	95	153	16	20	54	78	10	6	-	-	-	-	0	0
ALLHAT <sup>w188</sup>	pravastatin	5170	5185	0.6	82	88*		66	75	232	258	-	-	209	231	53	56	-	-	-	-	-	-
PLAC 1 & 2 <sup>w171,w189</sup>	pravastatin	281	278	1.2	9	11		2	11	3	7	-	-	1	5	0	2	-	-	-	-	-	-
REGRESS <sup>w83,w171</sup>	pravastatin	450	434	1.2	6	6		4	9	-	-	-	-	2	4	0	0	-	-	-	-	-	-
PREDICT <sup>w100</sup>	pravastatin	347	348	1.0	7	5		-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-
PMSG <sup>w101</sup> †	pravastatin	530	532	1.3	0	7		-	-	-	-	-	-	0	3	0	0	6	1	0	0	0	0
	pravastatin	83		1.1	1			3						0	0	0	0	-	-	-	-	-	-
	probucol	82	81	0.8	1	6		1	5					0	0	0	0	-	-	-	-	-	-
FAST <sup>w190</sup> †																							
Heart Protection Study <sup>w191,w192</sup> †	simvastatin	10269	10267	1.0	188	208		162	226	548	778	-	-	462	618	96	119	182	163	11	6	5	3
HS <sup>w156</sup>	simvastatin	2221	2223	1.7	114	137		69	105	159	271	27	49	70	98	14	12	33	49	6	1	1	0
SCAT <sup>w193</sup>	simvastatin	230	230	1.1			17 13 ‡							4	7	2	2	-	-	-	-	-	-
MAAS <sup>w144</sup>	simvastatin	193	188	1.3			8 3 ‡			6	5			1	2	0	0	0	0	-	-	0	0
CIS <sup>w194</sup>	simvastatin	129	125	1.4			2 7 ‡							0	0	0	0	-	-	-	-	-	-
HATS <sup>w195</sup>	simvastatin+niacin 38	38	38	1.2	1	1		0	2	0	2			0	2	0	2	-	-	-	-	-	-
All trials																		449	383	55	43	8	5

The expansion of the acronyms is given in the citations

±Alanine aminotransferase; "elevated" defined as ≥ 3 times upper limit of normal (>2 for ACAPS, HPS)

§Creatine phosphokinase; "elevated" defined as ≥ 10 times upper limit of normal in the absence of myocardial infarction

\*Numbers of ischaemic heart disease events by time period estimated from published survival curves

†Most but not all participants were in the specified category of disease on entry or no disease on entry

\*\* 61 & 62 in participants without and 74 & 69 with known vascular disease on entry

‡In these trials numbers of events were available for the first two years but not the first and second years separately

||After adjusting the EXCEL trial result for the fourfold greater number of treated than placebo subjects